Departement of Pharmaceutical Sciences
Institute for Pharmaceutical Biology
Klingelbergstrasse 50 - 4056 Basel
Tel: +41/61/267 14 75 - Fax: +41/61/267 14 74
mail: (office)


1 Pharmaceutical-biological research

Central themes of our research interests are small molecules of biogenic origin and their biological and pharmacological actions.
Natural products have been so far the most prolific source for drugs, and they continue to provide templates and inspiration for the development of new drug substances.


Penicillin G Penicillin G
click to enlarge

Antibiotic; inhibits murein synthesis in bacterial cell wall

Rapamycin Rapamycin G
click to enlarge

Immune suppressant; inhibits synthesis of IL-2 and other growth promoting lymphokines

Galanthamine Galanthamine
click to enlarge

Alzheimer drug; acetylcholine esterase inhibitor and cholinergic

Artemisinin Artemisinin
click to enlarge

Antimalarial; lead for clinically used semisynthetic derivatives

Taxol Taxol
click to enlarge

Anticancer agent; stabilizes microtubules

 

Natural products are invaluable tools for fundamental biomedical research. They have been decisive for numerous important discoveries in cell biology and pharmacology.

 

Forskolin Forskolin
click to enlarge

activator of adenylate cyclase

Nicotine

prototypical agonist of nicotinic ACh receptors

Phorbol

12-myristate 13-acetate

potent activator of protein kinase C

Staurosporine Staurosporine
click to enlarge

prototypical protein kinase inhibitor

Aconitine Aconitine
click to enlarge

activator of tetrodotoxin-sensitive sodium channels


Over 200'000 secondary metabolites have been identified to date. This number, however, represents only a fraction of the biosynthetic capabilities of living organisms.

The enormous structural diversity of natural products is the result of co-evolutive selection processes. One can reasonably assume that most of the secondary metabolites synthesized by an organism have some purpose for the producer.

Natural products have evolved to interact with proteins of target organisms, typically lower organisms such as bacteria, fungi, insects etc. Given the highly conserved nature of numerous proteins and protein domains, structurally homologous proteins exist in humans even though their function may sometimes have changed. It is not accidental that natural products interact with human proteins and, therefore, represent a unique pool of molecules with drug-like properties.


| 1 2 3 4 next all |




top
about